Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Emergent BioSolutions Q3 2026 Results: Net Loss of $32.7M

Emergent BioSolutions reported total assets of $995.2 million as of September 30, 2026, a decrease from $1,318.6 million at year-end 2025. The company is navigating significant debt obligations under a new 2026 Term Loan Agreement and is focused on its medical countermeasure (MCM) contracts with the U.S. government and the commercial performance of NARCAN Nasal Spray.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue110.0231.1
Profit before tax-36.457.6
Net income-32.751.2
EPS (diluted, $ a share)$-0.64$0.91

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-52.4%
Operating margin-33.9%
Source

10-Q filed with the SEC, NYSE: EBS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Emergent BioSolutions Inc.: key numbers

Share price
$5.81Close, Nov 16
Market cap
$299M
Shares outstanding
51.42MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Emergent BioSolutions Inc.

All →
4:08 PM ET 8-K
Contract Win

Emergent BioSolutions Wins $22.3M Contract from U.S. Department of War

Emergent BioSolutions received a $22.3 million modification exercising an option under an existing IDIQ contract to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. Deliveries will begin in 2026 with a $7.4 million initial shipment and continue through 2027 to support anthrax pre-exposure prophylaxis for all branches of the U.S. military.

Value
$22.3M
Counterparty
U.S. Department of War
Term
through 2027
4:07 PM ET 8-K
Financial Results

Emergent BioSolutions Financial Results

Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million, a 52% decrease year-over-year, and a net loss of $32.7 million. The results were primarily driven by the company's biodefense and naloxone portfolios as it continues a multi-year strategic transformation and turnaround.

Term
Q3 2026

“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation.”

Joe Papa, president and chief executive officer

“We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.”

Joe Papa, president and chief executive officer
7:48 AM ET 8-K
Leadership Change

Emergent BioSolutions Leadership Change

Richard Lindahl will retire as CFO of Emergent BioSolutions effective December 31, 2026, remaining as an advisor through March 2027. Frank Vargo, the company's current VP and Treasurer, has been appointed Interim CFO effective January 1, 2027.

3:45 PM ET Form 4
Insider Selling

Emergent BioSolutions Insider Donald W. DeGolyer Sells $126K of Stock

Donald W. DeGolyer sold 17,800 shares of Emergent BioSolutions Inc. at $7.09 a share, worth $126K in total on Oct 7, 2026. Shares held after the trade: 111,921 (-13.7%).

Value
$126K
Shares
17,800
Price
$7.09
Holding change
-13.7%
Trade date
Oct 7, 2026
9:16 AM ET Form 4
Insider Selling

Emergent BioSolutions SVP, Products Business Paul Anthony Williams Sells $19.6K of Stock

Paul Anthony Williams, SVP, Products Business, sold 3,000 shares of Emergent BioSolutions Inc. at $6.53 a share, worth $19.6K in total on Oct 1, 2026. Shares held after the trade: 156,098 (-1.9%).

Value
$19.6K
Shares
3,000
Price
$6.53
Role
SVP, Products Business
Holding change
-1.9%
Trade date
Oct 1, 2026
4:03 PM ET 8-K
Investor Presentation

Emergent BioSolutions Investor Presentation

Emergent BioSolutions CEO Joseph C. Papa is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed a formal investor presentation deck as an exhibit, which outlines its strategy for combating public health threats and provides updates on its medical countermeasure portfolio, including CYFENDUS and NARCAN.

Counterparty
H.C. Wainwright

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.